Clinical Trial Update: AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update shows AB-101, in combination with a B-cell depleting monoclonal antibody, is being studied in lupus nephritis (WHO Class III/…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• AB-101
• B-cell depleting monoclonal antibody

Snippet

Sponsor: Artiva Biotherapeutics, Inc. | Conditions: Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV | Phase 1 | Status: ACTIVE_NOT_RECRUITING